Skip to content
approvedOther

Lutetium-177 DOTATATE

Also known as: Lutathera, ¹⁷⁷Lu-DOTATATE, Lutetium Lu 177 dotatate, ¹⁷⁷Lu-oxodotreotide

Lutetium-177 DOTATATE (Lutathera) is a radiolabeled somatostatin analog peptide FDA-approved in 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It combines the somatostatin analog octreotate (TATE) with the radioactive isotope lutetium-177 via the chelator DOTA, enabling targeted delivery of beta radiation directly to tumor cells expressing somatostatin receptors (primarily SSTR2). This peptide receptor radionuclide therapy (PRRT) represents one of the most successful examples of theranostic medicine, where the same peptide targeting mechanism is used for both imaging and therapy.

3 cited references·5 researched benefits

Quick Answer

Lutetium-177 DOTATATE (Lutathera) is a radiolabeled somatostatin analog peptide FDA-approved for somatostatin receptor-positive neuroendocrine tumors. It delivers targeted beta radiation to SSTR2-expressing tumor cells while sparing normal tissue. The landmark NETTER-1 trial demonstrated 79% reduction in risk of disease progression or death compared to high-dose octreotide LAR. Administered as 4 IV infusions at 8-week intervals, it is one of the most effective treatments for advanced GEP-NETs.

Key Facts

Mechanism
Lutetium-177 DOTATATE consists of three components: (1) octreotate (TATE), a somatostatin analog peptide with high affinity for SSTR2 receptors overexpressed on neuroendocrine tumor cells; (2) DOTA, a macrocyclic chelator that stably binds the radioisotope; and (3) lutetium-177 (¹⁷⁷Lu), a beta-emitting radionuclide with a half-life of 6.7 days. After IV administration, the peptide binds SSTR2 on tumor cell surfaces and is internalized via receptor-mediated endocytosis. The internalized ¹⁷⁷Lu emits beta particles (maximum energy 498 keV, maximum tissue penetration ~2 mm) that cause DNA double-strand breaks and lethal radiation damage to the tumor cell and nearby cells (crossfire effect). The concurrent low-energy gamma emissions (208 keV) allow post-therapy SPECT/CT imaging to verify tumor targeting.
Research Status
approved
Half-Life
~6.7 days (lutetium-177 physical half-life)
Molecular Formula
C₆₅H₉₀LuN₁₄O₁₉S₂
Primary Use
Other
Table of Contents

Benefits

  • Dramatic progression-free survival improvement — NETTER-1 trial showed 79% reduction in risk of progression or death vs high-dose octreotide LARstrong
  • Overall survival benefit — post-hoc analysis showed median OS of 48 months vs 36.3 months for control armstrong
  • High objective response rate — 18% partial/complete response rate with an additional 35% minor responses or stable diseasestrong
  • Symptom improvement — significant reduction in carcinoid syndrome symptoms (flushing, diarrhea) and improvement in quality of lifestrong
  • Targeted therapy — delivers radiation specifically to SSTR2-expressing tumors, minimizing damage to normal tissuesstrong

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous infusion7.4 GBq (200 mCi) per cycleEvery 8 weeks for 4 cyclesAdministered as a slow IV infusion over 30 minutes in a nuclear medicine facility. Each cycle is preceded and followed by amino acid solution infusion (lysine/arginine) over 4 hours for renal protection. Total cumulative activity: 29.6 GBq (800 mCi) over 4 cycles. Complete blood counts and renal function must be monitored before each cycle. Treatment delayed if platelets <75,000 or absolute neutrophil count <1,500.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nausea and vomiting — occur during or shortly after infusion in 50-60% of patients; co-administered amino acids (for renal protection) contributecommon
  • Bone marrow suppression — lymphopenia in ~50%, thrombocytopenia in 10-25%, neutropenia in 5-10%; usually mild and reversiblecommon
  • Renal toxicity — radiation exposure to kidneys (SSTR expression in proximal tubules); amino acid co-infusion provides renal protectionserious
  • Fatigue — reported in 25-40% of patients, typically mild to moderate and lasting days to weeks after each cyclecommon
  • Myelodysplastic syndrome/acute leukemia — rare but serious long-term risk (~2-3%) from cumulative bone marrow radiationserious
  • Hepatotoxicity — risk in patients with extensive liver metastases receiving high radiation doses to the liverserious

Frequently Asked Questions

What is peptide receptor radionuclide therapy (PRRT)?
PRRT is a form of targeted radiotherapy that uses radiolabeled peptides to deliver radiation directly to tumors expressing specific receptors. In the case of Lutathera, the somatostatin analog peptide (TATE) homes in on SSTR2 receptors overexpressed on neuroendocrine tumor cells. The attached radioisotope (lutetium-177) then irradiates the tumor from within. This "theranostic" approach uses the same targeting mechanism for both diagnosis (with gallium-68 DOTATATE PET/CT imaging) and therapy — if the tumor lights up on the diagnostic scan, it will be targeted by the therapeutic agent.
How do patients qualify for Lutathera treatment?
Patients must have: (1) a confirmed diagnosis of well-differentiated (grade 1-2) GEP-NET, (2) positive somatostatin receptor expression confirmed by gallium-68 DOTATATE PET/CT scan (tumor uptake must exceed liver background), (3) progressive disease on standard somatostatin analog therapy, and (4) adequate bone marrow and renal function. Ki-67 index should be below 20%. Patients with very poorly differentiated (grade 3) tumors or those with low SSTR expression are not good candidates.
Is Lutathera radioactive — are there safety precautions?
Yes. Lutetium-177 emits beta and gamma radiation. After each treatment, patients are mildly radioactive for several days. Safety precautions include: limiting close contact with children and pregnant women for 7 days, sleeping in a separate bed for 7 days, using a separate bathroom when possible, flushing the toilet twice, and frequent handwashing. Most radiation is cleared through urine within 24-48 hours. Radiation exposure to household contacts is very low — equivalent to a fraction of a CT scan — but precautions are standard protocol.
Can Lutathera be repeated after the initial 4 cycles?
Retreatment with additional Lutathera cycles is being studied and is used in some centers on a compassionate basis for patients who initially responded but later progressed. Clinical data on retreatment (typically 4 additional cycles) show response rates of 20-30% in previously treated patients. However, cumulative risks to bone marrow and kidneys increase, so careful patient selection is required. The NETTER-2 trial and other ongoing studies are investigating optimal retreatment protocols.

References

  1. 1
    Phase 3 trial of ¹⁷⁷Lu-DOTATATE for midgut neuroendocrine tumors (NETTER-1)(2017)PubMed ↗
  2. 2
    Overall survival and updated progression-free survival with Lutathera in the NETTER-1 study(2018)PubMed ↗
  3. 3
    Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: current status and future directions(2017)PubMed ↗

Latest Research

Last updated: 2026-02-19